Business Daily Media

Men's Weekly

.

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

GUANGDONG, CHINA AND BAGSVÆRD, DENMARK - Media OutReach Newswire - 24 March 2025 - The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL's wholly-owned subsidiary The United Bio-Technology (Hengqin) Co.

, Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.

Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251. United Biotechnology will retain the rights for UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan. United Biotechnology is eligible to receive an upfront payment of 200 million US dollars and potential milestone payments of up to 1.8 billion dollars from Novo Nordisk, as well as tiered royalties on net sales outside of Chinese mainland, Hong Kong, Macau, and Taiwan.

"Novo Nordisk is dedicated to providing improved treatment options for people living with obesity, type 2 diabetes, and other cardiometabolic diseases. The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment options that cater to the diverse needs of people living with these highly prevalent diseases," said Martin Holst Lange, executive vice president for Development at Novo Nordisk. "We look forward to building on United Biotechnology's scientific work and further exploring the potential best-in-class properties of UBT251 across cardiometabolic disease indications."

United Biotechnology recently completed a randomized, double-blind, placebo-controlled phase 1b trial in China designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple subcutaneous injections of UBT251 in people with overweight or obesity.

A total of 36 patients were enrolled in three different dose groups (1mg, 1mg/3mg, 1mg/3mg/6mg). Each group adopted a dose titration method, with subcutaneous injection once a week for 12 consecutive weeks.

The safety profile of UBT251 was consistent with incretin-based therapies. The most common adverse events were gastrointestinal and the vast majority were mild to moderate in severity. In the highest dose group, the average weight of the people who completed the trial decreased by 15.1% from baseline, while the average weight of people in the placebo group increased by 1.5% from baseline.

"We are pleased to announce our exclusive license agreement with Novo Nordisk for UBT251. As a leading global biopharmaceutical company, Novo Nordisk holds a strong position in the treatment of chronic diseases," said Mr. Tsoi Hoi Shan, the Chairman of TUL. "TUL is committed to strengthening its presence in the treatment of chronic diseases, including endocrine and metabolic disorders, while actively expanding its footprint in global markets. We believe that Novo Nordisk's expertise will play a key role in accelerating the global development of UBT251."

This collaboration represents a pivotal milestone in TUL's ongoing efforts to establish a global strategic presence and demonstrates its commitment to innovation-driven transformation. TUL will continue to foster scientific innovation, advance high-quality and sustainable development, and accelerate the establishment of a globally competitive framework for manufacturing, R&D, and commercialization.

The closing of this transaction is subject to applicable regulatory clearance and other customary closing conditions.
Hashtag: #TUL

The issuer is solely responsible for the content of this announcement.

About UBT251

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has demonstrated potent activity on all three receptors in a preclinical setting.

UBT251 is categorized as a Class 1 innovative drug in China, being developed by United Biotechnology for multiple indications. To date, UBT251 has been approved for clinical trials in China in adult type 2 diabetes, overweight or obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), and chronic kidney disease (CKD), and for clinical trials in the United States in adult type 2 diabetes, overweight or obesity, and CKD.

United Biotechnology recently initiated a phase 2 trial for UBT251 in people with overweight or obesity in China.

About TUL and United Biotechnology

Founded in 1990, TUL (HKEX: 3933) is mainly engaged in the research and development, production and sales of pharmaceuticals, and ranks among the leading integrated pharmaceutical companies in China. TUL currently boasts seven production bases, covering intermediate products, bulk medicine , finished products, veterinary drugs, empty capsule casings, and medical devices, with the sales networks dotted across nearly 80 countries and regions. United Biotechnology, located in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, serves as the biopharmaceutical R&D headquarter of TUL. United Biotechnology focuses on the development of high-end biopharmaceuticals to treat major chronic diseases. For more information, please visit .

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit , , , and .

News from Asia

Chubb Life Hong Kong Launches Chubb 1792 Club: A New Era in Tailored Wealth Management Services

With a legacy of excellence, expertise, and a bold vision, Chubb Life HK is meeting rising demand for sophisticated, future-focused financial planning through bespoke legacy and wealth solutions HO...

Octa broker's take on the upcoming NFP report

KUALA LUMPUR - Media OutReach Newswire - 2 July 2025 - This Thursday at 12:30 p.m. UTC, the U.S. Bureau of Labor Statistics will release its highly anticipated Nonfarm Payroll (NFP) report...

OneMagnify India earns Best Place to Work certification for the fourth consecutive year

CHENNAI, INDIA - Media OutReach Newswire - 2 July 2025 - OneMagnify, a global leader in marketing, data, and technology solutions, has once again been recognized as a Best Place to Work in India ...

BeauEver Secures NZ Prime Minister’s Support in Historic China Summit to Accelerate Global Skincare Expansion

SHANGHAI, CHINA - Media OutReach Newswire - 2 July 2025 - At the 2025 China–New Zealand Trade Innovation Summit, New Zealand Prime Minister, the Right Hon. Christopher Luxon, witnessed the officia...

Central Europe Technologies recognized as one of the Best Places to Work in Romania for 2025

BUCHAREST, ROMANIA - Media OutReach Newswire - 2 July 2025 – Central Europe Technologies has been officially recognized as one of the Best Places to Work in Romania for 2025. Central Europe Techno...

CDNetworks Selected as Strategic Partner by Petrolimex Aviation to Bolster Cybersecurity with AI-Powered Cloud Platform

SINGAPORE - Media OutReach Newswire - 3 July 2025 - CDNetworks, the APAC-leading network to deliver edge as a service, today announced that Petrolimex Aviation, a major provider of aviation fuel...

Trade Crypto Without Purchasing It: Octa Broker About Crypto-CFDs

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 3 July 2025 - Crypto volatility poses both potentially spectacular possibilities and enormous risks. For example, by investing in crypto assets o...

Tia Lee Graces the Cover of ELLE Malaysia: A Journey of Empowerment, Evolution, and Expression

HONG KONG SAR - Media OutReach Newswire - 3 July 2025 - Global fashion and music icon Tia Lee (Lee Yu Fen) takes center stage on the cover of ELLE Malaysia, where she reflects on her multifaceted ...

Porsche Design Tower Bangkok Offers a Culinary Voyage into Iconic Living

STUTTGART, GERMANY / HONG KONG SAR - Media OutReach Newswire - 25 June 2025 - Porsche Design Tower Bangkok hosted an exclusive dinner event in a private estate villa in Hong Kong, offering esteeme...

Persona5: The Phantom X Officially Launched Today in Southeast Asia. Surpasses One Million Pre-Registrations. Log In Now to Claim Free Rewards.

Available on mobile and PC NOW. TAIPEI, TAIWAN - Media OutReach Newswire - 3 July 2025 - The highly anticipated turn-based JRPG Persona5: The Phantom X is officially launched today on iOS, Android...

Beyond borders: Building a scalable strategy for international hiring

For many Australian businesses, growth increasingly depends on thinking beyond local borders.  As wage pressures rise, and specialised talent pool...

The Next Generation of Maritime Sustainable Solutions

As organizations globally seek innovative ways to improve sustainability and their impact on Earth, the American Waterways Operators (AWO), a lead...

Demand for Home Batteries surges as Federal Rebate Kicks In

A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...

Why Sport Remains the Safest Bet in an Uncertain World

When Rome was in crisis, its leaders did not retreat to the Senate. They went to the circus. To the chariot races. To the gladiators. Sport was no...

THE FINE LINE WITHIN HILARIOUS SIGNAGE DESIGN FAILS

It seems like design failures still occur in today’s modern branding era, despite rigorous rounds of approvals behind the scenes. One signage show...

Deputy Announces Exclusive Global Partnership with Predelo to Bring AI to Shift-Based Businesses

Deputy, the global people platform for shift-based businesses, has announced an exclusive partnership with Predelo, an AI Decision Agent-as-a-Serv...

Sell by LayBy